Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer
about
Molecular interaction of a kinase inhibitor midostaurin with anticancer drug targets, S100A8 and EGFR: transcriptional profiling and molecular docking study for kidney cancer therapeuticsBioinformatic analysis reveals a pattern of STAT3-associated gene expression specific to basal-like breast cancers in human tumorsRegulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7An Inducible TGF-β2-TGFβR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases.Deguelin induces apoptosis by targeting both EGFR-Akt and IGF1R-Akt pathways in head and neck squamous cell cancer cell lines.In vivo induction of apoptosis by fucoxanthin, a marine carotenoid, associated with down-regulating STAT3/EGFR signaling in sarcoma 180 (S180) xenografts-bearing mice.EGFR regulates the development and microarchitecture of intratumoral angiogenic vasculature capable of sustaining cancer cell intravasation.Suppression of Proinflammatory and Prosurvival Biomarkers in Oral Cancer Patients Consuming a Black Raspberry Phytochemical-Rich Troche.Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma.Tyrosine kinase domain mutations of EGFR gene in head and neck squamous cell carcinoma.MicroRNA-135b and Its Circuitry Networks as Potential Therapeutic Targets in Colon CancerThe dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.Oxidative metabolism enhances the cytotoxic and genotoxic properties of the soy isoflavone daidzein.Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies-A review.
P2860
Q28544659-E5849E5E-20D2-45FE-8DEE-DCAD72FBFEB4Q34144598-1A624911-ADBD-464D-AFF4-09B2EBE3E5EEQ34463471-D03ED17A-8D6E-4AE0-84AA-FBED110C5ABFQ35577672-D3EDB71A-3139-4C27-9301-9B378CADA874Q35667885-D106E0C5-0E3A-4B53-9CF5-2FC58D0DEAB5Q36329883-C6E7BA42-0D81-48B1-B73B-4DDB2AF460B3Q36360133-30AD8C18-6529-4609-86CF-5ED490F344FDQ36608739-D18BC849-2766-4B2E-916F-F7A6CF4FA2C1Q37690668-0FC5A7BE-A02F-42EA-9E1A-9EB0B5741410Q37712380-8B2C9C0A-95E4-4DB0-A6D5-E1CF587874C0Q38155170-AC1FF201-8AF7-463B-84B0-5C3A03E5BCD1Q38995499-B0A300D5-D636-4BAD-84AD-2F8FBF99899CQ44801717-2DAFAA7F-2393-42EE-8CDA-154647377286Q50419857-22934364-10E6-4575-8845-E7A0D244C9E4
P2860
Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer
@ast
Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer
@en
type
label
Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer
@ast
Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer
@en
prefLabel
Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer
@ast
Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer
@en
P2093
P2860
P356
P1433
P1476
Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer
@en
P2093
Masato Fujii
Yasumasa Kato
Yutaka Tokumaru
P2860
P304
P356
10.1155/2012/986725
P577
2012-03-26T00:00:00Z